VB - Vanguard Small-Cap ETF
| Previous Close | 151.25 |
| Open | 151.03 |
| Bid | 150.29 x 200 |
| Ask | 150.38 x 400 |
| Day's Range | 150.16 - 151.34 |
| 52 Week Range | 130.46 - 155.86 |
| Volume | 97,629 |
| Avg. Volume | 601,714 |
| Net Assets | 84.48B |
| NAV | 146.96 |
| PE Ratio (TTM) | N/A |
| Yield | 1.38% |
| YTD Return | -0.29% |
| Beta (3y) | 1.00 |
| Expense Ratio (net) | 0.05% |
| Inception Date | 2004-01-26 |
- Zacks•2 months ago
How to Invest with Confidence
Did the recent stock market correction give you jitters? You're not alone. Find out how to take charge of your investing.
- ETF Trends•2 months ago
Rising Interest Rates Does Not Spell Doom for Stock ETFs
The Federal Reserve typically hikes interest rates to obviate an overheating economy during the later stages of an economic cycle, typically foreshadowing the eventual end of a bull market. Nevertheless, ...
Market Realist•2 months agoTaking Stock of Globus Medical’s Recent Acquisitions
Globus Medical (GMED) recently launched a robotic surgical navigation device. Since its inception in 2003, Globus Medical has launched more than 180 products. Globus Medical acquired KB Medical, a Switzerland-based robotic developer, in June 2017.
- Investopedia•3 months ago
Top 3 Small-Cap ETFs for 2018
There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.
- Market Realist•3 months ago
A Deeper Look at Nektar Therapeutics’ Licensing Agreements
Nektar Therapeutics (NKTR) has entered into a number of licensing and collaboration agreements for research, development, and commercialization with various healthcare companies, including Eli Lilly (LLY), AstraZeneca (AZN), and Amgen (AMGN). Under these agreements, Nektar is entitled to receive license fees, milestone payments, royalties, and payments for manufacturing and supplying Nektar’s proprietary PEGylation materials.
- Investopedia•5 months ago
Top 3 Small-Cap ETFs for 2017
There's a case to be made that small-cap ETFs will outperform in the final months of 2017. Here are a few to consider.
- InvestorPlace•5 months ago
5 Small-Cap ETFs That Knock Out the Competition
When it comes to investing, small-cap stocks beat large caps as the best ETFs to buy. After all, it’ll take a lot of a behemoth like International Business Machines Corp. (NYSE:IBM) to get the ship moving. Which is why small-cap stocks have tacked on an extra 253% in cumulative extra returns over large-cap stocks.
- InvestorPlace•5 months ago
The 3 Best Vanguard ETFs to Get Your ‘Risk On’
While risk-takers will eschew broader-scoped exchange-traded funds (ETFs) for the glory (and profits) of individual stocks, ETFs are a relevant component of any investing strategy. While the profit potential is greatest with a bet on a single company, the opposite is also true. Over the long run, the law of averages makes choosing the best Vanguard ETFs particularly compelling.
- Investor's Business Daily•6 months ago
Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
- Investor's Business Daily•6 months ago
Dow Sells Off As Boeing, GE Weigh; Chance To Buy Small Caps?
Key U.S. stock indexes sold off Wednesday as earnings reports continued and amid renewed talk about changes to 401(k) contribution limits.
- Zacks•6 months ago
PowerShares Launches Small-Cap Equity ETF
PowerShares rolls out small-cap U.S. equity ETF.
- Zacks•7 months ago
Hot Areas of Last Week and Their ETFs
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
- Market Realist•7 months ago
Nuplazid Sees Increasing Physician Intent to Prescribe in 2017
Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
- Morningstar•8 months ago
Small Caps: The Easy Game for Active Managers?
The odds may be better for small-cap managers, but they're still long.
- Zacks•8 months ago
Here's Why Small Cap ETFs Are Underperforming
U.S. small cap ETFs suffer on account of growing uncertainty around Trump's pro-growth policies.
- Zacks•8 months ago
U.S. Small Business Confidence Up in July: ETFs in Focus
U.S. small business activity improves in July; beats estimates.
- Market Realist•9 months ago
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
- Market Realist•9 months ago
Where Abiomed Plans to Expand Impella CP’s Label
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.
- Market Realist•10 months ago
These Are Align Technologies Key Demand Drivers in North America
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
- Motley Fool•11 months ago
What Happened in the Stock Market Today
Palo Alto Networks leaped, Hewlett Packard Enterprise fell, and major market averages started June on a positive note.
- Motley Fool•11 months ago
ETF Basics: How to Choose the Right Exchange-Traded Fund for You
Here's how exchange-traded funds work, why they benefit retail investors, and how to pick the right ETFs for your portfolio.
- Market Realist•11 months ago
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
- Harvest Exchange•11 months ago
So Far, So Good for Small-Cap Earnings
With arrival of spring comes first-quarter earnings announcements throughout the stock market. Large-cap companies generally report a little earlier, business results are better than 1Q's GDP might imply, and the news so far for both small- and ...
- Harvest Exchange•last year
Small Cap Owning Large Cap, Mass Hysteria!
By Roger Nusbaum, AdvisorShares ETF Strategist The title of this post is a play on the bit in the movie Stripes when Bill Murray talks about dogs and cats living together. You probably heard about the niche ETF (naming names is difficult for ...
- Market Realist•last year
Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016
Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.
